Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL469503 | 0.84 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2HPGDEPHX2NR1H4 | |
| SCHEMBL9706241 | 0.82 | EGFR (0.58) | CA1CA2ALDH1A1SMN1; SMN2NR1H4 | |
| SCHEMBL8162349 | 0.82 | CA1 (0.50) | CA1CA2ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL8579799 | 0.82 | CA1 (0.50) | CA1CA2ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL1004649 | 0.82 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2HPGDEPHX2NR1H4 | |
| SCHEMBL16761855 | 0.81 | MLYCD (0.51) | CA1CA2ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL16242064 | 0.81 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2HPGDEPHX2NR1H4 | |
| SCHEMBL4485529 | 0.81 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2HPGDEPHX2NR1H4 | |
| SCHEMBL505778 | 0.81 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2HPGDEPHX2NR1H4 | |
| SCHEMBL9449839 | 0.80 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2HPGDEPHX2NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011285-A1 | CYP11A1 INHIBITORS | ORION CORPORATION (FI) | 2025-01-09 | — | — | US | disclosed |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
| EP-3558981-B1 | PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORP (FI) | 2021-05-26 | — | — | EP | disclosed |
| WO-2018191146-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-10-18 | — | — | WO | disclosed |
| US-20160376293-A1 | NICKEL PRE-CATALYSTS AND RELATED COMPOSITIONS AND METHODS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-12-29 | — | — | US | disclosed |
| US-9382281-B2 | Nickel pre-catalysts and related compositions and methods | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382281-B2 | Nickel pre-catalysts and related compositions and methods | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-07-05 | — | — | US | disclosed |
| EP-0920425-A1 | SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL-AMINO)PIPERIDINES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1999-06-09 | — | — | EP | disclosed |
| CN-1211246-A | Novel substituted N-methyl-N-(4-(1H-benzimidazol-2-yl-amino) piperidin-1-yl)-2-(aryl) butyl) benzamides useful for treatment of allergic diseases | HOECHST MARION ROUSSEL INC (US) | 1999-03-17 | — | — | CN | disclosed |
| CN-1211248-A | Novel substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) [1,4] diazepan-1-yl)-1-(aryl) butyl) benzamides useful for treatment of allergic diseases | HOECHST MARION ROUSSEL INC (US) | 1999-03-17 | — | — | CN | disclosed |
| CN-1207097-A | Novel substituted 4- (1H-benzimidazol-2-yl) [1,4] diazepanes useful for the treatment of allergic diseases | HOECHST MARION ROUSSEL INC (US) | 1999-02-03 | — | — | CN | disclosed |
| EP-0888336-A1 | NOVEL SUBSTITUTED N-METHYL-N-(4-(4-(1H-BENZIMIDAZOL-2-YL-AMINO)P IPERIDIN-1-YL)-2-(ARYL)BUTYL)BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1999-01-07 | — | — | EP | disclosed |
| CN-1202894-A | Substituted 4-(1H-benzimidzol-2-yl-amino) piepridines useful for the treatment of allergic diseases | HOECHST MARION ROUSSEL INC (US) | 1998-12-23 | — | — | CN | disclosed |
| EP-0874843-A1 | NOVEL SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL) 1,4]DIAZEPANES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997030989-A1 | NOVEL SUBSTITUTED N-METHYL-N-(4-(4-(1H-BENZIMIDAZOL-2-YL-AMINO)PIPERIDIN-1-YL)-2-(ARYL)BUTYL)BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1997-08-28 | — | — | WO | disclosed |
| WO-1997022604-A1 | NOVEL SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL)[1,4]DIAZEPANES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1997-06-26 | — | — | WO | disclosed |
| WO-1997019074-A1 | SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL-AMINO)PIPERIDINES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1997-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011285-A1 | CYP11A1 INHIBITORS | CYP11B1, CYP19A1, CYP11B2 | CA1 1930/4885CA2 1656/4885ALDH1A1 188/4885 |
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | RHEB, KRAS, NRAS | CA1 3602/4885CA2 3765/4885ALDH1A1 3621/4885 |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | RHEB, GDI2, KRAS | CA1 4355/4885CA2 3982/4885ALDH1A1 3277/4885 |
| US-20160376293-A1 | NICKEL PRE-CATALYSTS AND RELATED COMPOSITIONS AND METHODS | SOD1, NIT2, MPO | CA1 248/4885CA2 660/4885ALDH1A1 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.